A Less Toxic Antifungal Agent | June 17, 2013 Issue - Vol. 91 Issue 24 | Chemical & Engineering News
Volume 91 Issue 24 | p. 10 | News of The Week
Issue Date: June 17, 2013

A Less Toxic Antifungal Agent

Medicinal Chemistry: Modified version of amphotericin B will drive search for effective analogs
Department: Science & Technology | Collection: Life Sciences
News Channels: Organic SCENE, JACS In C&EN
Keywords: amphotericin B, antifungal agent
Amphotericin B, with mycosamine in blue and the analog’s eliminated 2'-hydroxyl group in red.
A line structure of amphotericin B.
Amphotericin B, with mycosamine in blue and the analog’s eliminated 2'-hydroxyl group in red.

The natural product drug amphotericin B is a last-resort treatment for life-threatening fungal infections. But it can cause serious side effects, including liver damage, convulsions, and heart failure. Less-toxic versions of amphotericin B have been reported, although none have been approved for use.

University of Illinois, Urbana-Champaign, chemistry professor Martin D. Burke and coworkers are trying again. They report a modification that eliminates the drug’s toxicity in human cells, giving hope for a new class of less-toxic derivatives (J. Am. Chem. Soc. 2013, DOI: 10.1021/ja403255s).

Amphotericin B is a large cyclic compound with a small appendage called mycosamine. Two years ago, Burke and coworkers showed that mycosamine binding to the fungal sterol ergosterol enables the drug to kill fungi (C&EN, March 21, 2011, page 51).

The researchers also believe that mycosamine binding to cholesterol in patients causes the drug’s side effects. They now find that deleting mycosamine’s 2'-hydroxyl group gives an analog that doesn’t bind cholesterol, retains most of the parent compound’s potency, and in lab studies eliminates side effects in human cells.

Natural product specialist Michio Murata of Osaka University calls the reduced toxicity a “surprise.” He says the derivative could be “an important lead compound for developing efficacious and safe antifungal drugs.”

Amphotericin B expert Erick Carreira of Swiss Federal Institute of Technology, Zurich, cautions that the paper’s experimental data on cholesterol interactions are subject to interpretations different from those made by Burke’s group. Carreira notes that it remains to be seen whether a derivative “generated through multistep synthetic sequences, as described in the paper, will be sufficient to displace the natural product from the clinic.”

Another amphotericin B expert, Maciej Baginski of Gdansk University of Technology, in Poland, says the study’s experiments don’t conclusively establish the 2'-hydroxyl group’s role in sterol binding. But he notes that if the new analog’s lack of toxicity “is confirmed by further studies, including in vivo animal experiments, it will open a new branch of amphotericin B derivatives that may eventually bring a new lead molecule.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment